RENTON HOLLINGS 4
4 · ANAPTYSBIO, INC · Filed Jul 17, 2024
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
RENTON HOLLINGS
Director
Transactions
- Exercise/Conversion
Common Stock
2024-07-15−10,000→ 30,925 totalExercise: $6.93Exp: 2025-07-05→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2024-07-15$6.93/sh+10,000$69,300→ 11,950 total - Sale
Common Stock
2024-07-15$30.50/sh−7,103$216,668→ 4,847 total - Sale
Common Stock
2024-07-15$30.98/sh−2,897$89,754→ 1,950 total
Footnotes (4)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025.